Ajanta Pharma Limited
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic a… Read more
Market Cap & Net Worth: Ajanta Pharma Limited (AJANTPHARM)
Ajanta Pharma Limited (NSE:AJANTPHARM) has a market capitalization of $4.50 Billion (₹389.74 Billion) as of March 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #5812 globally and #201 in its home market, demonstrating a 6.97% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ajanta Pharma Limited's stock price ₹3119.50 by its total outstanding shares 124935624 (124.94 Million).
Ajanta Pharma Limited Market Cap History: 2015 to 2026
Ajanta Pharma Limited's market capitalization history from 2015 to 2026. Data shows growth from $1.18 Billion to $4.50 Billion (11.92% CAGR).
Index Memberships
Ajanta Pharma Limited is a constituent of 5 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY PHARMA
CNXPHARMA
|
$58.09 Billion | 2.60% | #14 of 20 |
|
NIFTY 500
NIFTY500
|
$1.33 Trillion | 0.11% | #187 of 500 |
|
NIFTY MIDCAP 150
NIFTYMIDCAP150
|
$342.17 Billion | 0.44% | #82 of 150 |
|
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
|
$535.62 Billion | 0.28% | #111 of 400 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$1.39 Trillion | 0.11% | #186 of 750 |
Weight: Ajanta Pharma Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Ajanta Pharma Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ajanta Pharma Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.09x
Ajanta Pharma Limited's market cap is 0.09 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.43x
Ajanta Pharma Limited's market cap is 0.43 times its annual earnings
10.29x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.60 Billion | $17.08 Billion | $4.01 Billion | 0.09x | 0.40x |
| 2017 | $1.34 Billion | $19.16 Billion | $5.07 Billion | 0.07x | 0.26x |
| 2018 | $1.08 Billion | $20.60 Billion | $4.69 Billion | 0.05x | 0.23x |
| 2019 | $895.52 Million | $20.16 Billion | $3.87 Billion | 0.04x | 0.23x |
| 2020 | $1.51 Billion | $25.62 Billion | $4.68 Billion | 0.06x | 0.32x |
| 2021 | $2.08 Billion | $28.47 Billion | $6.54 Billion | 0.07x | 0.32x |
| 2022 | $1.70 Billion | $32.84 Billion | $7.13 Billion | 0.05x | 0.24x |
| 2023 | $2.94 Billion | $37.43 Billion | $5.88 Billion | 0.08x | 0.50x |
| 2024 | $4.23 Billion | $42.09 Billion | $8.16 Billion | 0.10x | 0.52x |
| 2025 | $3.99 Billion | $46.48 Billion | $9.20 Billion | 0.09x | 0.43x |
Competitor Companies of AJANTPHARM by Market Capitalization
Companies near Ajanta Pharma Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Ajanta Pharma Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Ajanta Pharma Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Ajanta Pharma Limited's market cap moved from $1.18 Billion to $ 4.50 Billion, with a yearly change of 11.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹4.50 Billion | +12.66% |
| 2025 | ₹3.99 Billion | -5.57% |
| 2024 | ₹4.23 Billion | +43.66% |
| 2023 | ₹2.94 Billion | +73.44% |
| 2022 | ₹1.70 Billion | -18.22% |
| 2021 | ₹2.08 Billion | +37.48% |
| 2020 | ₹1.51 Billion | +68.63% |
| 2019 | ₹895.52 Million | -16.70% |
| 2018 | ₹1.08 Billion | -19.83% |
| 2017 | ₹1.34 Billion | -16.02% |
| 2016 | ₹1.60 Billion | +35.08% |
| 2015 | ₹1.18 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Ajanta Pharma Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.50 Billion USD |
| MoneyControl | $4.50 Billion USD |
| MarketWatch | $4.50 Billion USD |
| marketcap.company | $4.50 Billion USD |
| Reuters | $4.50 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.